B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome
Open Access
- 28 February 2006
- journal article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 8 (2) , R51
- https://doi.org/10.1186/ar1912
Abstract
B cell-activating factor (BAFF) has a key role in promoting B-lymphocyte activation and survival in primary Sjögren's syndrome (pSS). The cellular origin of BAFF overexpression in salivary glands of patients with pSS is not fully known. We investigated whether salivary gland epithelial cells (SGECs), the main targets of autoimmunity in pSS, could produce and express BAFF. We used quantitative RT-PCR, ELISA and immunocytochemistry in cultured SGECs from eight patients with pSS and eight controls on treatment with IL-10, tumor necrosis factor α (TNF-α), IFN-α and IFN-γ. At baseline, BAFF expression in SGECs was low in pSS patients and in controls. Treatment with IFN-α, IFN-γ and TNF-α + IFN-γ increased the level of BAFF mRNA in pSS patients (the mean increases were 27-fold, 25-fold and 62-fold, respectively) and in controls (mean increases 19.1-fold, 26.7-fold and 17.7-fold, respectively), with no significant difference between patients and controls. However, in comparison with that at baseline, stimulation with IFN-α significantly increased the level of BAFF mRNA in SGECs of pSS patients (p = 0.03) but not in controls (p = 0.2), which suggests that SGECs of patients with pSS are particularly susceptible to expressing BAFF under IFN-α stimulation. Secretion of BAFF protein, undetectable at baseline, was significantly increased after IFN-α and IFN-γ stimulation both in pSS patients (40.8 ± 12.5 (± SEM) and 47.4 ± 18.7 pg/ml, respectively) and controls (24.9 ± 8.0 and 9.0 ± 3.9 pg/ml, respectively), with no significant difference between pSS and controls. Immunocytochemistry confirmed the induction of cytoplasmic BAFF expression after stimulation with IFN-α and IFN-γ. This study confirms the importance of resident cells of target organs in inducing or perpetuating autoimmunity. Demonstrating the capacity of SGECs to express and secrete BAFF after IFN stimulation adds further information to the pivotal role of these epithelial cells in the pathogenesis of pSS, possibly after stimulation by innate immunity. Our results suggest that an anti-BAFF therapeutic approach could be particularly interesting in pSS.Keywords
This publication has 62 references indexed in Scilit:
- Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictorsAnnals of the Rheumatic Diseases, 2006
- Association Between Circulating Levels of the Novel TNF Family Members APRIL and BAFF and Lymphoid Organization in Primary Sjögren’s SyndromeJournal of Clinical Immunology, 2005
- Extrasalivary lymphoma development in Sjögren's syndrome: Clonal evolution from parotid gland lymphoproliferation and role of local triggeringArthritis & Rheumatism, 2003
- Recent advances in understanding molecular mechanisms in the pathogenesis and antibody profile of Sjögren’s syndromeCurrent Rheumatology Reports, 2003
- Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndromeArthritis & Rheumatism, 2002
- Salivary gland lymphomas in patients with Sjögren's syndrome may frequently develop from rheumatoid factor B cellsArthritis & Rheumatism, 2000
- Malignant lymphoma in primary Sj gren's syndrome: A multicenter, retrospective, clinical study by the European concerted action on Sj gren's syndromeArthritis & Rheumatism, 1999
- BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte StimulatorScience, 1999
- Identification and Characterization of a Novel Cytokine, THANK, aTNF Homologue That ActivatesApoptosis, Nuclear Factor-κB, and c-Jun NH2-Terminal KinaseJournal of Biological Chemistry, 1999
- Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses.1997